



Recipient Risk Factors for Cardiac Transplantation

Monica Colvin, MD, MS, FAHA

University of Michigan

Cutting Edge of Transplantation 2016

Phoenix, AZ



CUTTING EDGE OF
TRANSPLANTATION

RESOLVING THE ORGAN SHORTAGE



PRACTICE



POLICY



POLITICS



AMERICAN SOCIETY OF
TRANSPLANTATION

FEBRUARY 25-27, 2016 • PHOENIX, ARIZONA

Conflict of Interest Disclosure


- I have no relevant financial relationships to disclose.



AMERICAN SOCIETY OF
TRANSPLANTATION

© 2016 AST

CUTTING EDGE OF TRANSPLANTATION 2016
RESOLVING THE ORGAN SHORTAGE
PRACTICE | POLICY | POLITICS



CTRD
Cleveland Clinic
ISHLT



Age

No significant effect on mortality

- *Rickenbacher et al. Eur H J 1997-54 yrs*
- *Crespo-Leiro et al. Transplant Proc 1999- 65 yr*
- *Baron et al. Transplant Proc 1999- 60 yrs*
- *Blanche et al. JTCV 70 yrs*

Effect on mortality


- *Borkon et al. JHLT 1999-55 yrs (56% vs. 78% at 5 yrs)*



Pulmonary Hypertension

- *Murali et al. AHJ 1993*
 - Preoperative TPG \geq 15 associated with increased 0-2 day mortality
- *Erikson et al. JHLT 1990*
 - Prep PVR, PAS, and PVRI not predictive of short-term mortality.
 - 6-month mortality TPG \geq 12 mmHg 24% vs 5% TPG <12 mmHg; p = 0.003
 - 12-month mortality 36% vs 5%; p = 0.0005
- *Frigerio et al. G Ital Cardiol 1995*
 - Right atrial pressure \geq 12, pulmonary vascular resistance index \geq 8, and transpulmonary gradient \geq 15 associated with increased mortality and RV failure
- PVR > 3 (or more)

Retransplant



Poor predictors
Transplant during
the first year
Transplant for
graft failure

1y 70% vs. 85%
10yr 38% vs. 69%

Lund et al. JHLT 2014



AMERICAN SOCIETY OF
TRANSPLANTATION

© 2016 AST

CUTTING EDGE OF TRANSPLANTATION 2016
RESOLVING THE ORGAN SHORTAGE
PRACTICE | POLICY | POLITICS

Changing Risk Factors: CTRD

Variable name	p-value	Relative risk
Early-phase recipient variables		
Date of transplant	<0.0001	2.0 (10 years)
Age	0.001	1.3 (60 vs 45), no VAD
Idiopathic cardiomyopathy	0.05	0.8
Ischemic cardiomyopathy	0.05	0.8
Number of previous sternotomies	<0.0001	1.2 (1 vs 0)
Creatinine clearance at listing	0.0002	1.1 (50 vs 90)
Serum creatinine at transplant	<0.0001	1.3 (1.5 vs 1.0)
Mean RA pressure at pre-transplant cath	0.0009	1.2 (13 vs 5)
Non-parous female	0.004	1.8
VAD support at time of transplant	0.13	0.9 (VAD vs no VAD at age 30)
Interaction of age and VAD support	0.02	1.7 (VAD vs no VAD at age 60)

N=7013
26 institutions
41,213 pt-yrs
1990-2008

Tallaj et al. JHLT 2014

Risk Factors > 1 year

Late-phase recipient variables		
Date of transplant	0.0002	Interaction, see below
Age	<0.0001	1.5 (2005 vs 1995; age 25 y)
Interaction of transplant date and age	<0.0001	0.6 (2005 vs 1995; age 60 y)
African-American ethnicity	<0.0001	2.6 (black vs non-black; age 25 y)
Interaction of age and ethnicity	0.01	1.6 (black vs non-black; age 60 y)
Grade of diabetes	<0.0001	1.4 (none vs IDDM)
Hypertrophic cardiomyopathy	0.06	0.5
Ischemic cardiomyopathy	0.006	1.2
History of smoking—quit >6 months before listing	0.006	1.2
History of smoking within 6 months of listing	<0.0001	1.7
Percent ideal body weight	<0.0001	1.2 (125% vs 100%)
History of peripheral vascular disease	0.002	1.4

Tallaj et al. JHLT 2014




AMERICAN SOCIETY OF
TRANSPLANTATION

© 2016 AST

CUTTING EDGE OF TRANSPLANTATION 2016
RESOLVING THE ORGAN SHORTAGE
PRACTICE | POLICY | POLITICS

IMPACT Score

- UNOS registry,
N=21,000+, 1997-
2008
- Outcome: 1-year
mortality
- 50-point scoring
system with 12
recipient-specific
variables



Weiss, Ann Thorac Surg, 2011

Identifying Recipients at Risk for Graft Failure


- UNOS data 1997-2009
- n=671, 45% grafts failed
- 35 recipient variables
- Adjusted for donor variables (donor age and ischemic time)

Kilic et al. ATS 2012

Recipient Risk Factors

Recipient Covariate	Univariate Analysis		Multivariable Analysis	
	OR (95% CI)	p Value	OR (95% CI)	p Value
Age (increasing)	1.02 (1.01–1.03)	0.002	1.02 (1.01–1.04)	0.005
Serum creatinine (increasing)				<0.001
Mechanical ventilation				<0.001
TransCAD	-0.78 (−0.78–1.09)		1.09 (1.09)	0.12
Primary graft failure	2.87 (1.66–4.95)	<0.001	1.21 (0.59–2.49)	0.60
Intraaortic	2.18 (1.20–3.16)	0.01	1.14 (0.56–1.72)	0.72

Increasing age
Serum creatinine
Mechanical ventilation



- Decade increase in recipient age conferred a 20% increase in graft failure
- 1-mg/dL increase in creatinine increased graft failure odds by 59%
- Mechanical ventilation increased graft failure odds by > 3.5-fold

Kilic et al. ATS 2012

The High Risk Recipient: UNOS data 2001-2007




Risk Factors	Weight	Odds Ratio	Upper 95% CI	Lower 95% CI	p Value
Comorbidities					
Recipient age: >70 yo	2.1	2.069	1.387	3.086	0.000
Recipient age: 55-70 yo	1.2	1.216	1.075	1.375	0.002
Previous cardiac surgery	1.3	1.269	1.117	1.442	0.000
Etiology: congenital	2.3	2.210	1.754	3.068	0.000
Etiology: amyloidosis	1.8	2.210	1.754	3.798	0.154
Diabetes complicated by CVA	1.4	2.210	1.754	2.022	0.138
eGFR < 33	2.8	2.210	1.754	3.333	0.000
eGFR 33-53	1.4	2.210	1.754	1.584	0.000
Total bilirubin > 2	1.7	2.210	1.754	2.020	0.000
Acuity					
Intubated	1.8	1.784	1.338	2.379	0.000
Hospitalized	1.2	1.172	1.038	1.323	0.011
Mechanical Support					
RVAD-only	4.7	4.739	1.982	11.331	0.000
ECMO	3.9	3.852	1.993	7.446	0.000
Extracorporeal LVAD	2.7	2.748	1.836	4.114	0.000
Total artificial heart	2.4	2.400	1.311	4.391	0.005
Paracorporeal LVAD	1.2	1.250	0.969	1.612	0.086

Recipient age > 70
 Congenital diagnosis
 GFR<33
 MCS (ECMO and RVAD)

n=11,703

Primary outcome-1 yr graft failure

Hong et al. ATS 2011



Hong et al. ATS 2011

Recipient Risk Factors 1-yr Program Specific Reports December 2015

<http://srtr.org/csr/current/modtabs.aspx>

New First-Year, Adult Graft Survival Model

Candidate/Recipient Factors

- Diabetes
- Highest Ed. Level
- History of Cigarette Use
- Any Previous Malignancy
- Race
- Urgency Status at Transplant
- Age
- BMI
- CO (L/min)
- Prior CABG
- Multiple Prior Cardiac Surgeries
- Other Prior Cardiac Surgery
- CMV serostatus
- Dialysis since listing
- EBV serostatus
- Patient on ECMO at Tx
- HBV Surface Antigen
- HCV serostatus
- Patient on LVAD at Tx
- Patient on RVAD at Tx
- Patient on TAH at Tx
- Medical Condition at Tx
- Serum Creatinine
- Total Bilirubin
- Patient on Life Support at Tx
- Previous Solid Organ Transplant
- Primary Diagnosis
- Primary Source of Payment
- PA (diastolic and systolic)
- PCW (mean)
- Transfusions since listing
- Patient on Ventilator at Tx





AMERICAN SOCIETY OF
TRANSPLANTATION

© 2016 AST

CUTTING EDGE OF TRANSPLANTATION 2016
RESOLVING THE ORGAN SHORTAGE
PRACTICE | POLICY | POLITICS



Bilirubin at Transplant (mg/dL)



Dialysis at Transplant

Bilirubin
Dialysis
Drug-treated hypertension at listing

HR 1.6
HR 1.85
Drug-treated hypertension at listing HR 1.26




AMERICAN SOCIETY OF
TRANSPLANTATION



© 2016 AST

CUTTING EDGE OF TRANSPLANTATION 2016
RESOLVING THE ORGAN SHORTAGE
PRACTICE | POLICY | POLITICS

Recipient Age at Transplant




Recipient Height (cm)




Recipient Serum Cre


Recipient height HR 1.8
serum creatinine >1.5 HR 1.52




Recipient on Life Support (ECMO)



Recipient on VAD



Recipient on Ventilator



Important variables but not statistically significant

- Medical condition (ICU/hospitalized)
- Most recent cPRA/PRA
- PA systolic
- Previous heart transplant
- Race/Ethnicity
- Sudden death at listing

Long-term survival

Significant Covariates in Multivariable Logistic Regression for 10-Year Survival Covariates				
OR (95% CI)				
Recipient age < 55 y				
White race				
Decreasing ischemic time				
Diabetes and Mechanical ventilation decreased 10-yr survival				
Decreasing donor age	1.02 (1.01–1.02)	<0.001	1.01 (1.01–1.02)	<0.001
Annual center volume ≥ 9 OHT/y	1.19 (1.13–1.26)	<0.001	1.31 (1.17–1.47)	<0.001


> 10 years

Recipient age < 55 years
White race
Decreasing ischemic time

Diabetes and Mechanical ventilation decreased 10-yr survival

> 20 years

Recipient age < 45 years
Idiopathic cardiomyopathy



Kilic et al. ATS 2011

Jaramillo et al. Rev Esp Cardiol. 2013;66:797-802

Limitations to evaluating recipient risk factors

- Individual and center-specific practices
- Modifiable risks should be taken into account
- “Risk factors” markers of other factors (frailty, acuity)
- Interactions with donor factors